- Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 1998;34:977-86.
- Altaee MY, Johnson PJ, Farrant JM, Williams R. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer 1991;68:2051-5.
- Glimelius B, Hoffmann K, Sjöden PO, Jacobsso n G, Sellström H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996:7:593-600.
- Kvols LK, Moertel CG, O'Connel MJ, Schutt AJ, Rubin J, Haan RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663-6.
- Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600-6.
- Wymenga ANM, Eriksson B, Salmela PI, Jacobsen MB, VanCutsem EIDG, Fiasse RH, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999:17:1111-7.
- Cascinu S, Del Ferro E, Catalane G. A randomized trial of octreotide versus best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995:71:97-101.
- Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993;8:540-5.
- Ebert M, Friess H, Berger HG, Büchler MW. Role of octreotide in the treatment of pancreatic cancer. Digestion 1994;55:48-51.
- Raderer M, Hamilton G, Kurtaran A, Valencak J, Haberl I, Hoffmann O, et al. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer 1999:79:535-7.
- Tan CK, Podila PV, Taylor JE, Magomey DM, Wiseman GA, Gores GJ, et al. Human cholangiocarcinoma s express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 1995:108:1908-16.
- Sulkowski U, Dinse P, Haus U, Collins W. Regression of a distal bile duct carcinoma after treatment with octreotide for 6 months. Digestion 1997:58:407-9.
- Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer H, Walvik E, et al. Indium-111-DOTA-lanreotide : biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998:39:1928-36.
- Janson ET, Gobi A, Kalkner KM, Oberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 1996:56:2561 -5.
- Imam H, Eriksson B, Lukinius A, Janson E, Lindgren P, Wilander E, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997:36:607-14.
- Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmidt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeuti c use. Eur J Nucl Med 2000; 27:273-82.
- Raderer M, Hamilton G, Kurtaran A, Valencak J, Haberl I, Hofmann O, et al. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer 1999:79:535-7.
- Raderer M, Pangerl T, Leimer M, Valencak J, Kurtaran A, Hamilton G, et al. Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo. J Natl Cancer Inst 1998:90:1666-8.
Scandinavian Journal of Gastroenterology
Volume 37, 2002 - Issue 2